VANCOUVER, BRITISH COLUMBIA, Sep 29, 2010 (MARKETWIRE via COMTEX) -- iCo Therapeutics Inc. is pleased to announce that the Company's oral Amphotericin B program, "iCo-009", has been granted Orphan ...
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced that its wholly owned subsidiary, Amphotericin B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback